Loading
Cheryl Willman is a leukaemia genomics pioneer who leads Mayo Clinic's cancer centre across its three sites.
Cheryl Willman is Executive Director of the Mayo Clinic Comprehensive Cancer Center, including its Florida site, and previously directed the University of New Mexico Comprehensive Cancer Center. A haematopathologist, her genomic studies defined high-risk subtypes of acute lymphoblastic leukaemia, including work in Hispanic and Native American children. Her papers include a Blood study identifying novel cluster groups in paediatric high-risk B-precursor acute lymphoblastic leukaemia by gene expression profiling and a Nature Genetics study of ancestry and pharmacogenomics of relapse in the disease. She has led the Mayo Clinic cancer centre since 2021 and works on leukaemia genomics, health disparities and expression profiling.
Shares RNA sequencing & expression profiling, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares Blood, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares Blood, Acute myeloid leukaemia.